Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial.

Dietzsch, Stefan; Braesigk, Annett; Seidel, Clemens; Remmele, Julia; Kitzing, Ralf; Schlender, Tina; Mynarek, Martin; Geismar, Dirk; Jablonska, Karolina; Schwarz, Rudolf; Pazos, Montserrat; Weber, Damien C; Frick, Silke; Gurtner, Kristin; Matuschek, Christiane; Harrabi, Semi Ben; Glück, Albrecht; Lewitzki, Victor; Dieckmann, Karin; Benesch, Martin; ... (2022). Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie und Onkologie, 198(3), pp. 282-290. Springer 10.1007/s00066-021-01822-0

Preview

Text s00066-021-01822-0.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (802kB) | Preview

PURPOSE

In Germany, Austria, and Switzerland, pretreatment radiotherapy quality control (RT-QC) for tumor bed boost (TB) in non-metastatic medulloblastoma (MB) was not mandatory but was recommended for patients enrolled in the SIOP PNET5 MB trial between 2014 and 2018. This individual case review (ICR) analysis aimed to evaluate types of deviations in the initial plan proposals and develop uniform review criteria for TB boost.

PATIENTS AND METHODS

A total of 78 patients were registered in this trial, of whom a subgroup of 65 patients were available for evaluation of the TB treatment plans. Dose uniformity was evaluated according to the definitions of the protocol. Additional RT-QC criteria for standardized review of target contours were elaborated and data evaluated accordingly.

RESULTS

Of 65 initial TB plan proposals, 27 (41.5%) revealed deviations of target volume delineation. Deviations according to the dose uniformity criteria were present in 14 (21.5%) TB plans. In 25 (38.5%) cases a modification of the RT plan was recommended. Rejection of the TB plans was rather related to unacceptable target volume delineation than to insufficient dose uniformity.

CONCLUSION

In this analysis of pretreatment RT-QC, protocol deviations were present in a high proportion of initial TB plan proposals. These findings emphasize the importance of pretreatment RT-QC in clinical trials for MB. Based on these data, a proposal for RT-QC criteria for tumor bed boost in non-metastatic MB was developed.

Interest & Impact

Downloads

23 since deposited on 28 Dec 2022
17 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item